DexCom vs ONE Which Is More Lucrative?

DexCom and ONE are both companies in the burgeoning health technology sector, with a focus on improving healthcare outcomes through innovative products and solutions. DexCom is a leader in continuous glucose monitoring technology, while ONE is known for its digital health platform for managing chronic conditions. Both companies have experienced significant growth in recent years, attracting investor attention. In this comparison, we will dive into the financial performance, market trends, and growth potential of DexCom and ONE stocks.

DexCom or ONE?

When comparing DexCom and ONE, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between DexCom and ONE.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. DexCom has a dividend yield of -%, while ONE has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. DexCom reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, ONE reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with DexCom P/E ratio at 40.71 and ONE's P/E ratio at 2.39. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. DexCom P/B ratio is 14.01 while ONE's P/B ratio is 0.53.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, DexCom has seen a 5-year revenue growth of 2.21%, while ONE's is 0.41%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with DexCom's ROE at 31.20% and ONE's ROE at 25.25%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $69.66 for DexCom and zł103.50 for ONE. Over the past year, DexCom's prices ranged from $62.34 to $142.00, with a yearly change of 127.78%. ONE's prices fluctuated between zł40.60 and zł182.00, with a yearly change of 348.28%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.